{"id":390293,"date":"2019-12-30T00:00:00","date_gmt":"2019-12-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2019-biopharma-hepatocellular-carcinoma-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-28T11:24:21","modified_gmt":"2026-04-28T11:24:21","slug":"dlsfon0017-2019-biopharma-hepatocellular-carcinoma-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0017-2019-biopharma-hepatocellular-carcinoma-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Hepatocellular Carcinoma | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare \/ Amgen \/ Onyx), an angiogenesis inhibitor, was the only drug approved for advanced-stage patients until the recent approvals of Stivarga (Bayer HealthCare), Opdivo (Bristol-Myers Squibb \/ Ono Pharmaceuticals), Keytruda (Merck &#038; Co.), Lenvima (Eisai \/ Merck &#038; Co.), Cabometyx (Exelixis), and Cyramza (Eli Lilly). The late-phase development pipeline is predominantly focused on the advanced-stage HCC segment and encompasses a diverse range of mechanisms of action. Because the HCC market remains largely untapped, the developer of an efficacious therapy could reap high commercial rewards.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What is the current treatment landscape for HCC, and what clinical needs remain unfulfilled?<\/li>\n<li>Which drug classes are in the late-phase development pipeline, and which agents are the most promising?<\/li>\n<li>What are the clinically and commercially relevant drug-treatable patient populations in HCC, and how will drug-treatment rates change (if at all) over time?<\/li>\n<li>Which emerging therapies do we forecast to enter each of the HCC\u00a0market segments? What uptake and sales are these therapies anticipated to secure?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em>\u00a0provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><b>Markets covered:\u00a0<\/b>United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><b>Primary research:\u00a0<\/b>22 country-specific interviews with thought leaders (medical oncologists and hepatologists).<\/p>\n<p><b>Key companies:\u00a0<\/b>Bayer HealthCare\/Amgen\/Onyx , Bristol-Myers Squibb\/Ono Pharmaceutical, Merck &#038; Co., Eisai, Exelixis\/Ipsen.<\/p>\n<p><b>Key drugs:\u00a0<\/b>Nexavar, Stivarga, Opdivo, Lenvima, Keytruda, Cabometyx, Cyramza.<\/p>\n<p><b>Population segments in market forecast:\u00a0<\/b>Early-stage, first-line intermediate-stage, second-line intermediate-stage, first-line advanced-stage, and second-line advanced-stage hepatocellular carcinoma.<\/p>\n<p><b>Emerging therapies:\u00a0<\/b>Phase III: approximately 7 drugs; Phase II: approximately 15 drugs; coverage of select Phase I and preclinical products.<\/p>\n","protected":false},"template":"","class_list":["post-390293","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatocellular-carcinoma","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390293\/revisions"}],"predecessor-version":[{"id":576551,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390293\/revisions\/576551"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}